tirzepatide 2023 (Mounjaro) for the Treatment of Type 2 Diabetes Mellitus F.D.A. Approves New Obesity Drug

SURMOUNT-1 Study: In this phase 3 double-blind, randomised, controlled trial, 2539 adult patients were assigned in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period

Over time, persistent air bubbles mean you are consistently underdosed

This medicine is given as a shot under the skin of your stomach, thighs, or upper arm

At the same time, tirzepatide weight loss effects are significant for people struggling with obesity

Label your vial clearly with the reconstitution date using a permanent marker to avoid confusion

Goodnessoffit and other diagnostic plots indicated adequate fidelity between model predictions and observed data (Figure 1, Figure S1)